Copyright Reports & Markets. All rights reserved.

Global Oligonucleotide-based Therapies Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Oligonucleotide-based Therapies Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 Antisense Oligonucleotide
    • 1.2.3 Aptamer
    • 1.2.4 Other
  • 1.3 Market by Application
    • 1.3.1 Global Oligonucleotide-based Therapies Market Share by Application: 2020 VS 2026
    • 1.3.2 Neuromuscular Diseases
    • 1.3.3 Hepatic VOD
    • 1.3.4 Other
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Oligonucleotide-based Therapies Market Perspective (2015-2026)
  • 2.2 Global Oligonucleotide-based Therapies Growth Trends by Regions
    • 2.2.1 Oligonucleotide-based Therapies Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Oligonucleotide-based Therapies Historic Market Share by Regions (2015-2020)
    • 2.2.3 Oligonucleotide-based Therapies Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Oligonucleotide-based Therapies Players by Market Size
    • 3.1.1 Global Top Oligonucleotide-based Therapies Players by Revenue (2015-2020)
    • 3.1.2 Global Oligonucleotide-based Therapies Revenue Market Share by Players (2015-2020)
  • 3.2 Global Oligonucleotide-based Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Oligonucleotide-based Therapies Revenue
  • 3.4 Global Oligonucleotide-based Therapies Market Concentration Ratio
    • 3.4.1 Global Oligonucleotide-based Therapies Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Oligonucleotide-based Therapies Revenue in 2019
  • 3.5 Key Players Oligonucleotide-based Therapies Area Served
  • 3.6 Key Players Oligonucleotide-based Therapies Product Solution and Service
  • 3.7 Date of Enter into Oligonucleotide-based Therapies Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Oligonucleotide-based Therapies Breakdown Data by Type (2015-2026)

  • 4.1 Global Oligonucleotide-based Therapies Historic Market Size by Type (2015-2020)
  • 4.2 Global Oligonucleotide-based Therapies Forecasted Market Size by Type (2021-2026)

5 Oligonucleotide-based Therapies Breakdown Data by Application (2015-2026)

  • 5.1 Global Oligonucleotide-based Therapies Historic Market Size by Application (2015-2020)
  • 5.2 Global Oligonucleotide-based Therapies Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Oligonucleotide-based Therapies Market Size (2015-2026)
  • 6.2 North America Oligonucleotide-based Therapies Market Size by Type (2015-2020)
  • 6.3 North America Oligonucleotide-based Therapies Market Size by Application (2015-2020)
  • 6.4 North America Oligonucleotide-based Therapies Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Oligonucleotide-based Therapies Market Size (2015-2026)
  • 7.2 Europe Oligonucleotide-based Therapies Market Size by Type (2015-2020)
  • 7.3 Europe Oligonucleotide-based Therapies Market Size by Application (2015-2020)
  • 7.4 Europe Oligonucleotide-based Therapies Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Oligonucleotide-based Therapies Market Size (2015-2026)
  • 8.2 China Oligonucleotide-based Therapies Market Size by Type (2015-2020)
  • 8.3 China Oligonucleotide-based Therapies Market Size by Application (2015-2020)
  • 8.4 China Oligonucleotide-based Therapies Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Oligonucleotide-based Therapies Market Size (2015-2026)
  • 9.2 Japan Oligonucleotide-based Therapies Market Size by Type (2015-2020)
  • 9.3 Japan Oligonucleotide-based Therapies Market Size by Application (2015-2020)
  • 9.4 Japan Oligonucleotide-based Therapies Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Oligonucleotide-based Therapies Market Size (2015-2026)
  • 10.2 Southeast Asia Oligonucleotide-based Therapies Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Oligonucleotide-based Therapies Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Oligonucleotide-based Therapies Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11Key Players Profiles

  • 11.1 Biogen
    • 11.1.1 Biogen Company Details
    • 11.1.2 Biogen Business Overview
    • 11.1.3 Biogen Oligonucleotide-based Therapies Introduction
    • 11.1.4 Biogen Revenue in Oligonucleotide-based Therapies Business (2015-2020))
    • 11.1.5 Biogen Recent Development
  • 11.2 Sarepta Therapeutics
    • 11.2.1 Sarepta Therapeutics Company Details
    • 11.2.2 Sarepta Therapeutics Business Overview
    • 11.2.3 Sarepta Therapeutics Oligonucleotide-based Therapies Introduction
    • 11.2.4 Sarepta Therapeutics Revenue in Oligonucleotide-based Therapies Business (2015-2020)
    • 11.2.5 Sarepta Therapeutics Recent Development
  • 11.3 Jazz Pharmaceuticals
    • 11.3.1 Jazz Pharmaceuticals Company Details
    • 11.3.2 Jazz Pharmaceuticals Business Overview
    • 11.3.3 Jazz Pharmaceuticals Oligonucleotide-based Therapies Introduction
    • 11.3.4 Jazz Pharmaceuticals Revenue in Oligonucleotide-based Therapies Business (2015-2020)
    • 11.3.5 Jazz Pharmaceuticals Recent Development
  • 11.4 Bausch & Lomb
    • 11.4.1 Bausch & Lomb Company Details
    • 11.4.2 Bausch & Lomb Business Overview
    • 11.4.3 Bausch & Lomb Oligonucleotide-based Therapies Introduction
    • 11.4.4 Bausch & Lomb Revenue in Oligonucleotide-based Therapies Business (2015-2020)
    • 11.4.5 Bausch & Lomb Recent Development
  • 11.5 Alnylam Pharmaceuticals
    • 11.5.1 Alnylam Pharmaceuticals Company Details
    • 11.5.2 Alnylam Pharmaceuticals Business Overview
    • 11.5.3 Alnylam Pharmaceuticals Oligonucleotide-based Therapies Introduction
    • 11.5.4 Alnylam Pharmaceuticals Revenue in Oligonucleotide-based Therapies Business (2015-2020)
    • 11.5.5 Alnylam Pharmaceuticals Recent Development
  • 11.6 Dynavax Technologies
    • 11.6.1 Dynavax Technologies Company Details
    • 11.6.2 Dynavax Technologies Business Overview
    • 11.6.3 Dynavax Technologies Oligonucleotide-based Therapies Introduction
    • 11.6.4 Dynavax Technologies Revenue in Oligonucleotide-based Therapies Business (2015-2020)
    • 11.6.5 Dynavax Technologies Recent Development
  • 11.7 Kastle therapeutics
    • 11.7.1 Kastle therapeutics Company Details
    • 11.7.2 Kastle therapeutics Business Overview
    • 11.7.3 Kastle therapeutics Oligonucleotide-based Therapies Introduction
    • 11.7.4 Kastle therapeutics Revenue in Oligonucleotide-based Therapies Business (2015-2020)
    • 11.7.5 Kastle therapeutics Recent Development
  • 11.8 Akcea Therapeutics
    • 11.8.1 Akcea Therapeutics Company Details
    • 11.8.2 Akcea Therapeutics Business Overview
    • 11.8.3 Akcea Therapeutics Oligonucleotide-based Therapies Introduction
    • 11.8.4 Akcea Therapeutics Revenue in Oligonucleotide-based Therapies Business (2015-2020)
    • 11.8.5 Akcea Therapeutics Recent Development

12Analyst's Viewpoints/Conclusions

    13Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Oligonucleotide-based Therapies market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Oligonucleotide-based Therapies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Antisense Oligonucleotide
    Aptamer
    Other

    Market segment by Application, split into
    Neuromuscular Diseases
    Hepatic VOD
    Other

    Based on regional and country-level analysis, the Oligonucleotide-based Therapies market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Oligonucleotide-based Therapies market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Biogen
    Sarepta Therapeutics
    Jazz Pharmaceuticals
    Bausch & Lomb
    Alnylam Pharmaceuticals
    Dynavax Technologies
    Kastle therapeutics
    Buy now